Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Despite advances in screening and therapeutics cancer continues to be one of the major
causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely …

Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Head and neck squamous cell carcinomas (HNSCC) arising from the oral cavity, pharynx,
and larynx constitute the 6 th most common human cancer. Human papillomavirus (HPV) …

Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly
resistant to conventional radiation and chemotherapy, and is not amenable to effective …

Simple Summary The canonical WNT/β-catenin pathway is upregulated in cancers and
plays a major role in proliferation, invasion, apoptosis and angiogenesis. Recent studies …

Simple Summary Next-generation sequencing of head and neck squamous cell carcinoma
has revealed multiple new gene mutations, while simultaneously confirming the role of …

Background Amplification of EGFR and its active mutant EGFRvIII are common in
glioblastoma (GB). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted …

PARK7 is involved in many key cellular processes, including cell proliferation, transcriptional
regulation, cellular differentiation, oxidative stress protection, and mitochondrial function …